Six years ago I wrote the first version of this article. Back then the story was simple: foreign pharma giants like Amgen and Pfizer were buying stakes in Chinese biotechs, because China had fast patient recruitment and a market growing in every direction. That story is over. In 2026, the money runs the other way. Chinese biotechs are the ones licensing their drugs to AstraZeneca, Pfizer, and Eli Lilly, for tens of billions of dollars a deal. If your company still thinks of China as a place to sell products once they’re approved elsewhere, you’re already behind. Is your pipeline worth more in a Shanghai boardroom than in a European one right now? 🙂 For a growing number of drug classes, the honest answer is yes.
Philip Chen is CEO of Gentlemen Marketing Agency (GMA) in Shanghai. Our healthcare and life sciences clients used to ask us how to get funded in China. Now they ask how to get found, by Chinese hospitals, distributors, and increasingly by the Chinese biotechs shopping for a Western commercial partner.
China’s biotech industry is booming
There has been a step-change in the quantity and quality of Chinese biotech companies over the past few years, and the amount of capital flowing into the sector has followed.
China is no longer just the world’s second-largest healthcare market. It now accounts for roughly 30% of the entire global new-drug pipeline, according to China Briefing’s 2026 biopharma clusters report. That number would have sounded absurd back in 2020.
Experts still expect China to become a major hub for cancer treatments and metabolic disease drugs, obesity and diabetes especially, because the unmet need in both categories is enormous and the government keeps shortening the path from lab to approval.
The deal that first put this on Western radar goes back to 2020: Amgen took a $2.7 billion stake in Beijing-based BeiGene, with BeiGene selling three Amgen drugs in China and helping develop 20 new cancer treatments. At the time it looked like a one-off. It turned out to be the opening chapter.
The capital flow flipped: China is now the seller, not the target
By 2025 the direction of the money had reversed. Foreign pharma is no longer mainly buying equity in Chinese biotechs, it’s buying the rights to Chinese-discovered drugs and paying to bring them to the rest of the world. Cross-border out-licensing deals originating from China hit a record $135.7 billion in 2025, across 157 transactions, close to a third of global deal value, up from roughly a fifth just two years earlier.
The pace didn’t slow in 2026. Q1 alone brought roughly $60 billion in new out-licensing deals, a 73% jump year on year, according to reporting in the South China Morning Post. Average deal size climbed too: around $1.3 billion per deal so far this year, up 76% from 2025 and about six times the 2021 average.
The headline deal of the year: AstraZeneca signed an obesity-drug agreement with CSPC Pharmaceutical Group worth up to $18.5 billion, a $1.2 billion upfront payment plus milestones, for global rights (outside Greater China) to CSPC’s long-acting GLP-1 portfolio and its AI-assisted peptide discovery platform, according to Fierce Biotech. It wasn’t the only megadeal: Hengrui signed $15.2 billion with Bristol Myers Squibb, Innovent signed $10.5 billion with Pfizer, and Eli Lilly struck separate deals worth $8.5 billion with Innovent and $3.05 billion with Haisco.
Something changed under the surface too. The old model was buy the drug, take it home. The new model, what bankers in Shanghai now call Co-Co (co-development, co-commercialization), has multinationals treating a Chinese asset almost like a startup they’re building together: shared IP, shared trial data, sometimes a shared sales force inside China itself. If you’re a foreign biotech negotiating in Shanghai this year, expect the term sheet to look nothing like what your lawyers saw in 2021.
Where the money is landing: China’s three biotech clusters
Three clusters absorb almost all of this activity, and if you’re picking a China entry point, the cluster matters as much as the deal structure.
- Yangtze River Delta (Shanghai, Jiangsu, Zhejiang, Anhui): 70% of the sector’s R&D talent, and Zhangjiang Science City alone hosts over 1,700 biomedical companies, including seven of the world’s ten biggest drugmakers. Best suited to commercialization and manufacturing at scale.
- Beijing-Tianjin-Hebei: anchored around Zhongguancun Life Science Park, built for proximity to the National Medical Products Administration (NMPA), the regulator you’ll be dealing with directly. Best suited to drug discovery and regulatory strategy.
- Greater Bay Area (Guangdong, Hong Kong, Macao): as of December 2025, 63 drugs and 77 devices had cleared through its accelerated cross-border review pathway, across 71 institutions. Best suited to faster market access.
Recent commitments confirm where the majors are placing their bets: Roche put RMB 2.04 billion into a new Zhangjiang manufacturing site, AstraZeneca opened a commercial cell-therapy base in Lingang in March 2026 on top of an earlier $2.5 billion Beijing R&D and vaccine facility, and Sanofi committed EUR 1 billion to a Beijing insulin plant. None of these companies are hedging. They’re building for the long run.
Reasons for the increase in investments in China
China’s biopharmaceutical industry keeps expanding because of favorable underlying factors: fast economic growth, rising incomes, and growing demand for advanced treatments. The industry has become genuinely important to the national economy, and that draws attention from both private and public investors.
There are four main reasons for the sustained increase in investment:
- The growing number of genuinely science-led, R&D-heavy Chinese companies, not just generic manufacturers.
- The 2018 Hong Kong Stock Exchange (HKEX) rule change allowing pre-revenue biotechs to list. That access to capital markets is essential for an industry that burns cash for years before any revenue arrives.
- Faster drug approvals, thanks to standardized clinical trials, a better reimbursement process, and a modernized regulatory path through the NMPA.
- New in 2026: the patent cliff. Global pharma faces up to $200 billion in lost annual revenue between 2026 and 2030 as blockbuster patents expire, and Chinese pipelines are one of the fastest ways to refill a portfolio. That’s a big part of why deal sizes tripled almost overnight.
What biotech areas are gaining more interest?
The areas pulling in the most capital and deal activity right now: antibody-drug conjugates (ADC), T-cell engagers (TCE), bispecific and trispecific antibodies, siRNA, AI-assisted drug discovery, cell therapy (CAR-T especially), and radiopharmaceuticals. ADC, CAR-T, and multi-specific antibodies together make up the large majority of China’s out-licensing volume this year.
Why should biotech companies look to China for investment?
Legal changes and years of economic momentum keep opening new opportunities in China.
China has a huge population and a correspondingly large patient pool. Domestic science is advanced in several areas, but drug development still lags the West in others, so Chinese companies and investors actively want access to foreign expertise, and foreign biotechs are a natural source of it.
The government keeps adjusting regulation to make it easier for local companies to develop new products, and for banks and VCs to back promising foreign partnerships.
A drug can enter the Chinese market faster now, either through direct entry or by out-licensing to a Chinese partner, which means quicker returns if the drug performs.
How can foreign biotech investors succeed in China?
Cultural and language barriers are real, and most people who have actually closed a deal here will tell you the same thing: working through a partner who already has the relationships (关系, guanxi, the trust-based network Chinese business runs on) saves you eighteen months of expensive mistakes.
GMA has worked with healthcare and biotech brands like Arkopharma Laboratories to build their visibility and credibility in China. What we’ve learned doing that work directly is what the rest of this article is about.
Go digital: the key to success in China
With over 1.1 billion Chinese connected online in 2026, Chinese platforms dominate, and healthcare and biotech companies have to use them to build visibility, reputation, and product credibility. Digital marketing remains the most cost-effective channel, with the best return on investment of anything in the budget.
A quality healthcare website in Mandarin
Start with a Simplified Chinese website, hosted in China, so it’s actually visible on Baidu, still the search engine most Chinese patients and procurement teams check first. Before any purchase or consulting request, they’ll search your company on Baidu. In healthcare, transparency is the single biggest trust factor.
Pictures, content, and video matter. Chinese audiences read explanations closely and pay attention to doctor and researcher testimonials when health is on the line.
Baidu SEO is still essential to rank on page one for the keywords your buyers actually search. What’s new in 2026: DeepSeek and other Chinese AI assistants are increasingly the first stop for medical and scientific questions, and they pull answers from the same well-structured, authoritative Chinese content that ranks on Baidu. Skip the Chinese content work and you’re invisible in both places at once.
Working on forum community management to increase company reliability
Chinese consumers have been burned before by healthcare companies overselling on Baidu, and Baidu has since clamped down hard on paid healthcare results. That history is exactly why trust signals matter more in China’s healthcare sector than almost anywhere else. International healthcare brands able to invest in credibility-building work are the ones winning the buyers who can pay for it.
Forum and community management is still one of the best ways to build that reputation while ranking well on Baidu at the same time. These communities are themselves highly ranked, so relevant content surfaces on the keyword searches that matter.
Use social media to gain visibility in the Chinese market
China runs on social platforms, and healthcare is no exception. WeChat and Weibo still carry the largest audiences, but Xiaohongshu now functions as a search engine in its own right, especially for anything patients research before a purchase or a doctor’s visit. If you’re not showing up there, you’re missing a growing share of where Chinese healthcare research actually happens.
Social media has to be a core part of your China marketing strategy, not an afterthought bolted on after the website launches.
A case that shows why the mechanism matters more than the channel
Mark runs a European biotech reagent company, lab chemicals and diagnostic components sold to hospitals, universities, and diagnostics manufacturers. Not a Pfizer. A forty-person company with a solid product and almost no presence in China.
His first attempt: translate the English website into Chinese, hand it to a generic SEO agency, wait. Six months later, two inbound inquiries. Total.
The problem wasn’t the translation. The site was hosted outside China, so Baidu deprioritized it by default. And Chinese lab procurement managers don’t cold-contact a supplier they’ve never heard of. They check Zhihu (China’s Quora) and specialist chemistry forums first, to see if anyone credible vouches for the brand before they’ll even fill out a contact form.
What we changed: moved hosting to mainland China, rebuilt the Chinese site around real technical content (protocols, reagent specs, comparison data a lab manager actually needs), and got Mark’s own team answering questions on Zhihu and two specialist chemistry forums under their real names, not through an agency account. We also opened a WeChat official account aimed specifically at lab procurement staff, not consumers.
It worked because it matched how the buyer actually behaves. Baidu trusts domestically hosted, technically deep content. Chinese B2B buyers verify a supplier’s credibility through peer forums before they ever reach out. We weren’t running ads at strangers, we were showing up in the two places the buyer already checks before making contact.
Result: from an average of one or two inbound requests per quarter to 19 qualified RFQs over the following two quarters, three of which became signed distributor contracts within the year.
Questions we actually get asked about entering China’s biotech market
We’re a small biotech, not a multinational. Does any of this apply to us?
Yes, but the playbook looks different. The megadeals make headlines, but the volume of activity below that level, reagent suppliers, CROs, diagnostics companies, mid-size specialty pharma, is where most of GMA’s actual client work happens. You won’t get an $18 billion offer. You can absolutely get found by the right hospital, university lab, or distributor if your Chinese digital presence is built correctly.
Do we need a Chinese legal entity (WFOE) before we start marketing?
It depends what you’re selling. If you’re generating leads for a distributor to close, you can often start without one. If you plan to invoice in RMB, hold clinical data domestically, or hire staff in China, you’ll need a WFOE eventually. For anything touching patient data or clinical trials, get your regulatory counsel involved before you launch marketing, not after.
How long before we see real leads from China?
Budget four to eight months before qualified inbound starts arriving, longer in healthcare than in consumer goods because of the trust-building step described above. Anyone promising results in month one is either overselling or running paid ads at the wrong audience.
Should we license our drug to a Chinese partner or build our own commercial presence?
It depends on your cash runway and your appetite for control. Licensing gets you revenue and a partner who already has regulatory relationships and sales infrastructure, but you give up a share of the upside and some control over positioning. Building your own presence costs more and takes longer, but you keep the brand and the data. Most companies we talk to end up doing both: licensing the drug itself while building a smaller commercial and marketing footprint to control brand perception.
Is Baidu SEO still worth it now that everyone talks about DeepSeek and AI search?
Yes, and increasingly the two reinforce each other. Chinese AI assistants pull their answers from the same authoritative, well-structured Chinese-language content that ranks on Baidu. Neglect one and you’re weaker in both.
Read also:
- The Surprising Growth of the Hospital Market in China
- Baidu Rank Tracking: Optimize with Baidu Keyword Planner
- WeChat Integrated DeepSeek: What It Means for Brand Marketing in China
- Xiaohongshu as a Search Engine for Brands in 2026
GMA (Gentlemen Marketing Agency) builds the Chinese digital presence that hospitals, distributors, and increasingly Chinese biotechs themselves check before taking a foreign life sciences company seriously: a compliant Mandarin website hosted in China, Baidu SEO, WeChat and Xiaohongshu content, and the credibility-building work on forums and Zhihu that gets you found before you ever pitch anyone. See what that looks like for your sector, or contact us to talk through your entry into China’s biotech market.
